The global health landscape is evolving with Brazil battling bird flu-related trade restrictions, Nestle USA eliminating ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

At least 29% of young adults in Delhi show signs of lung damage in routine CT scans, including bronchiectasis and emphysema, ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

General Mills said organic sales could fall again in the current fiscal year as consumers continue to spend less on snacks, despite efforts to return to growth. Bumble to Cut 30% of Workforce; Raises ...

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly's launch ...

Weight loss drugs help manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP ...

The Weight Loss Revolution— that’s released on Wednesday provides a detailed insight into these weight management drugs and ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

COPENHAGEN - Danish drugmaker Novo Nordisk will launch its weight-loss drug Wegovy in India without any supply constraints, a ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...